AbbVie’s $2.5bn Rinvoq franchise reaches children as young as two after EU approval
The European Commission has approved Rinvoq for active polyarticular juvenile idiopathic arthritis in children aged two and older, adding another patient population to AbbVie’s rapidly growing immunology franchise and introducing a weight-based oral solution for younger patients.
